Lannett Eyes Another $11M In Savings With R&D Sea Change, Job Cuts
Plans To Shutter Two More Facilities In PA As Restructuring Continues
Executive Summary
Lannett unveiled another round of cost-saving initiatives alongside its financial Q2 earnings, including plans for a radical change for its R&D development.
You may also be interested in...
NYSE Gives Lannett Six Months To Meet Standards
US firm has received a notice of non-compliance from NYSE due to price of company’s shares. Lannett insists there is no immediate impact, but it is evaluating options, including “transactions that are subject to approval of Lannett’s stockholders.”
Lannett New York Listing Under Threat As FDA Says No On Advair
A strained balance sheet and share price has led the New York Stock Exchange to write to Lannett about its future listing, adding to its woes as the FDA confirmed it was not currently in a position to approve its partnered generic Advair Diskus asset.
Lannett To Close And Sell NY Liquids Plant As Part Of Restructuring Plans
Lannett is once again taking the axe to its operations in order to tighten its focus and save on costs, including the planned divestment of its liquids generics manufacturing facility in Carmel, New York.